European equities traded in the US as American depositary receipts were trending higher late Monday morning, rising 0.60% to 1,497.18 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical companies Cellectis (CLLS) and DBV Technologies (DBVT), which rose 5.2% and 4.7% respectively. They were followed by telecommunications operator Telefonica (TEF) and Spanish lender Banco Santander (SAN), which were up 4.2% and 3.7% respectively.
The decliners from continental Europe were led by pharmaceutical company Novo Nordisk (NVO) and biotech firm Evaxion (EVAX), which fell 2.8% and 2.3% respectively. They were followed by biopharmaceutical company argenx (ARGX) and semiconductor company Sequans Communications (SQNS), which were down 2.1% and 1.8% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies NuCana (NCNA) and Adaptimmune Therapeutics (ADAP), which advanced 19% and 5.1% respectively. They were followed by cruise line operator Carnival (CUK) and telecommunications operator Vodafone Group (VOD), which increased 5% and 3.5% respectively.
The decliners from the UK and Ireland were led by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Akari Therapeutics (AKTX), which dropped 2.8% and 2.5% respectively. They were followed by oil and gas company BP (BP) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which were off 2% and 1.9% respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。